Company intelligence / Profile preview

Suven Life Sciences

Hyderabad, Telangana, India

Ownership: Private
Development stage: Other

Overview

Suven Life Sciences is a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) drug discovery. It has multiple small-molecule programs targeting cognition, depression, pain, and neurodegenerative diseases. Lead assets include SUVN‑502 for Alzheimer’s disease in Phase 2A trials and SUVN‑911 for major depressive disorder in Phase 1. The company also provides contract research and manufacturing services globally.

Therapeutic areas: PsychiatryNeurologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

14 assets

masupirdine

13 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly & Company – CNS drug discovery collaborationUniversity of Minnesota – HIV drug development collaboration

Beyond the preview

Go deeper on Suven Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suven Life Sciences.

Explore the full profile